Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Wall Street Zen

Key Points

• Kiniksa Pharmaceuticals International's stock rating has been upgraded from "buy" to a "strong-buy" by Wall Street Zen, reflecting increased confidence in the company's performance.
• The stock has seen analysts set target prices ranging from $36.00 to $54.00, with a consensus target price of $41.17.
• Kiniksa recently reported earnings that exceeded expectations, with an EPS of $0.23 against a consensus estimate of $0.18, indicating strong financial health amid robust revenues.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report released on Sunday.

KNSA has been the topic of a number of other research reports. Wedbush restated an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Jefferies Financial Group increased their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th. Finally, Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 9th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $41.17.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ KNSA traded down $0.63 during mid-day trading on Friday, reaching $36.23. The company had a trading volume of 319,099 shares, compared to its average volume of 667,622. Kiniksa Pharmaceuticals International has a twelve month low of $17.82 and a twelve month high of $37.25. The stock has a market capitalization of $2.68 billion, a PE ratio of 905.98 and a beta of 0.20. The stock's 50 day moving average is $31.32 and its 200-day moving average is $26.77.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The business had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Insider Buying and Selling

In related news, CAO Michael R. Megna sold 11,000 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $34.84, for a total transaction of $383,240.00. Following the sale, the chief accounting officer directly owned 38,011 shares of the company's stock, valued at $1,324,303.24. This trade represents a 22.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Thomas Malley sold 78,233 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97. Following the sale, the director directly owned 12,546 shares in the company, valued at approximately $415,147.14. This trade represents a 86.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 562,271 shares of company stock valued at $18,716,309 in the last quarter. Insiders own 53.48% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new stake in Kiniksa Pharmaceuticals International during the first quarter worth about $301,000. GAMMA Investing LLC grew its position in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after buying an additional 568 shares in the last quarter. Deutsche Bank AG grew its position in Kiniksa Pharmaceuticals International by 177.1% during the first quarter. Deutsche Bank AG now owns 394,522 shares of the company's stock worth $8,762,000 after buying an additional 252,125 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in Kiniksa Pharmaceuticals International during the first quarter worth about $1,184,000. Finally, Nuveen Asset Management LLC grew its position in Kiniksa Pharmaceuticals International by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after buying an additional 54,361 shares in the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.